As the global economy mends, the 2021 growth of PD-1 and PD-L1 Inhibitors will have significant change from previous year. According to our (LP Information) latest study, the global PD-1 and PD-L1 Inhibitors market size is USD million in 2022 from USD 38690 million in 2021, with a change of % between 2021 and 2022. The global PD-1 and PD-L1 Inhibitors market size will reach USD 146540 million in 2028, growing at a CAGR of 21.0% over the analysis period.
The United States PD-1 and PD-L1 Inhibitors market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global PD-1 and PD-L1 Inhibitors market, reaching US$ million by the year 2028. As for the Europe PD-1 and PD-L1 Inhibitors landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main PD-1 and PD-L1 Inhibitors players cover Merck, Novartis, Bristol-Myers Squibb, and GlaxoSmithKline, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PD-L1 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Humanized IgG1(Immunoglobulin 1)
Humanized IgG4(Immunoglobulin 5)
Cytokine
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Oral
Subcutaneous Injection
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Merck
Novartis
Bristol-Myers Squibb
GlaxoSmithKline
Regeneron Pharmaceuticals
Eli Lilly and Company
Roche Genetech
AstraZeneca
Jiangsu HengRui Medicine Co., Ltd.
Curis Inc.
Aurigene